Kidron Miriam 4
4 · ORAMED PHARMACEUTICALS INC. · Filed Mar 31, 2026
Research Summary
AI-generated summary of this filing
Oramed CSO Miriam Kidron Surrenders 435,084 Shares for Taxes
What Happened Miriam Kidron, Chief Scientific Officer and a director of Oramed Pharmaceuticals (ORMP), disposed of 435,084 shares on 2026-03-30 to satisfy tax withholding obligations tied to vested restricted stock units. The shares were valued at $3.31 each (the prior trading day's close), for a total value of approximately $1,440,128. This was a tax-withholding-related disposition (routine), not an open-market sale for cash.
Key Details
- Transaction date: 2026-03-30; filing date: 2026-03-31 (timely).
- Shares surrendered/disposed: 435,084 at $3.31 per share; total value ≈ $1,440,128.
- Transaction code: F (shares used to satisfy tax withholding upon RSU vesting).
- Footnote: Shares used to satisfy withholding were valued at the closing price on the date immediately prior to vesting ($3.31) per filing.
- Shares owned after the transaction: not specified in this Form 4.
Context This was a cashless-type disposition to cover tax liabilities from RSU vesting (common practice) and does not necessarily indicate the insider's view of the company's stock. Tax-withholding dispositions are routine and are treated differently from deliberate open-market sales or purchases.
Insider Transaction Report
- Tax Payment
Common Stock
[F1]2026-03-30$3.31/sh−435,084$1,440,128→ 1,133,138 total
Footnotes (1)
- [F1]Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.